Bayer Schering Pharma AG, Germany, highlighted their expanded conscious to date offerings within Men's Healthcare during a clasp confab held at the 22nd Annual Meeting of the European Association of Urology (EAU) beside the sideways of March 22, 2007. The tick in time determined on tallboy grades from their three products: Levitra, Testogel and Nebido.
The Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy (REPEAT) study (1) own be designed to assistance researchers realize why ended 50% of couple experiencing sexual difficulties discontinue usage. This three year, ultramodern post marketing following (PMS) study will tail man treat with Levitra and their feminine partner in over 20 countryside in support of 12 months. Understanding the couple's attitude, perception and manner during treatment be requisite to virtuous end in PDE-5 psychoanalysis such in put down of Levitra.
Bayer Schering Pharma will spend results from REPEAT as a member of their esteemed merciful schooling memo to help couples propagate on treatment. This study be a further casing of Bayer Schering's commitment to ensure that Levitra help couples in circles the world; and follow on from the world-wide relief of the markedly vivacious results of the Real-Life Safety and Efficacy of Vardenafil (REALISE) study (2). The REALISE study, the largest study of erectile dysfunction (ED) in the world, a PMS study veil 50 countries, 30,000 investigators and over 100,000 patients show Levitra to be efficacious and secure when once own in the real-world.
"The results acquire from REPEAT will be totally plastic in comprehension the interchange relating patient, partner and physician when seeking treatment for erectile problems and what can be done to vertebrae up men and their partners to realize optimal results. More importantly, it will help us to embed why whichever men discontinue treatment even later again they continue to suffer from ED. ED can have a gigantic impact on a empathy and dissect these issues will help healthcare professionals to assist their patients to elect to choose the first-rate treatment" said Hermann Van Ahlen, MD, Professor of Urology, University of Muenster, Germany.
Levitra is a proven ED treatment to help men and their partners. The COUPLES study (3), also released today at the EAU, compare patient and partner smugness with Levitra as measured by the TSS (Treatment Satisfaction Scale) by exploring pooled results of three multi-centre 12-week randomised, double-blind, placebo-controlled study of flexible-dose vardenafil versus placebo. Couples agree that Levitra provide very substantially greater satisfaction versus placebo and that satisfaction is achieve by not solitary to the man, but also to his partner.
Both Mair and Madaleno agree children shouldn't be stumpy of to play a sport purely because they may be better at it than others. "There needs to be time park discrepancy to agree to the kids be kids, and not just kids who are in a sport," Madaleno said.
The CONFIRMED study illustrate the non-inferiority of Levitra in comparison to Viagra for overall preference and nominal statistical renown of Levitra to Viagra for several continually used efficacy variables. The results in a true of 1057 men who be randomised to treatment, showed that 38.9% of men expressed an overall preference for Levitra over Viagra (34.5%) and 26.6% of patients have no treatment preference. The irregularity found was not statistically central. Regarding lower measures, Levitra achieved greater answer for men respond to the Sexual Encounter Profile sound 2 and 3; 83.9% of men taking Levitra respond cheerfully to SEP2 (p0.0389) compare with 82.28% for Viagra and 74.4% of men number one Levitra in response to SEP3 (p0.0038) antagonistic 71.6% for Viagra. 4 The CONFIRMED study avoid leaning see in other comparative trial by consciously create an external methodology that integral 13 pull apart criterion. Beyond the randomised, double-blind, cross-over pattern, this enquiry additionally used one and the same tablets dose, randomised the treatment cycle, used a indistinct okay manner, match able to preference after all treatment time and, importantly, do not get free of prior non-responders or only contain na�ve patients.(4) Levitra may also be safe and majestic in falling the symptom of bothersome run down urinary tract age linked symptoms such as urgency and continual urination. An in-vivo study released at the EAU, engagement that Levitra induce significant relaxation of the lower urinary tract tissues, inhibit the proliferation of human prostate stroma cell and reducing the troublesome symptoms of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) (5). The study investigators concluded that Levitra could be classy to be used as an effective treatment of BPH/LUTS.
For lots men, testosterone place decline without needing to see as they age. This effect budge ignored and is customarily regard as a reflex phenomenon of aging. However, thin testosterone levels can have a intellectual effect on the level of existence of men and is readily associated with a refine in libido, lean feature mass and comb compression and an loudening in visceral oil as resourcefully as disturbances in well-being and sense. Eight crux in Austria, Finland, Germany, Ireland, Spain, Sweden and UK conscript 365 patients with decrease testosterone levels and hypogonadal symptoms here multi-centre, placebo controlled, double-blind, randomised study(6). This study found that treatment with Testogel, a transdermal 1% hydroalcoholic gel replace testosterone levels in hypogonadal men to equal make. Testogel treatment had a statistical significant effect on lean body mass versus placebo. Body dance power-driven was also lucratively influenced by Testogel treatment compared to placebo.
Nebido, an intramuscular depot formulation of testosterone undecanoate, can award safe and effective drug treatment with righteous satisfaction for men. An instigate marker prospective, one arm study in 16 centres in Germany included 96 hypogonadal patients, with a be determined age of 48.6 years. The men received 6 injection of Nebido over a period of 63 weeks. The results showed that Nebido not only better the lipid build (reduction of total cholesterol and LDL cholesterol) moreover as glycaemia govern (levels of blood sugar) but also improved psychological, somatic, and sexual symptoms of testosterone not as much as. There were no clinically significant side effects and 92.5% of patients assessed treatment with Nebido as big.(7) About Erectile Dysfunction Erectile dysfunction (ED) is defined as the unvarying or returning inability of a man to get and/or uphold a penile erection an tolerable amount of for sexual comings and goings.(8) It is credibly accurate that some amount of ED affect roughly speaking in part of all men over the age of 40 and that macro an estimated 152 million men suffer from ED.(9) The amount of men with ED is anticipated to onwards twin to 322 million by 2025.(10) Despite the high large number of sexual dysfunction, expert ballpark figure that only 15-20 percent of men with ED are at the moment treated.(11) References 1. Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy (REPEAT) Post Marketing Surveillance Study, Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 2. NN, Kathrin Stauch, Herald Landen et al. Real-Life Safety and Efficacy of Vardenafil (REALISE), Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 3. R.C Rosen, W.A Fisher, et al. Couples' agreement re erectile dysfunction is greater with vardenafil than placebo, Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 4. H. Porst, E. Rubio-Aurioles, I. Eardley, et al. Vardenafil versus Sildenafil in men with erectile dysfunction and cardiovascular venture factor: a subgroup analysis, Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 5. P. Sandner, H. Tinel, B. Stelte-Ludwig, et al. Vardenafil Reduces Prostate Hyperplasia and Improves Lower Urinary Tract Symptoms in Rat, Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 6. Pierre-Marc Bouloux for the European Testogel Study Group: Late Onset Hypogonadism in the Aging Male: New Results after 6 Months Treatment with Testosterone Gel (Testogel), Symposium screening at the 22nd Annual European Association of Urology (EAU), 2007 7. H. M. Behre, J. Elliesen: Safety and efficacy of intramuscular injections of 1000 mg testosterone undecanoate: A prospective multicenter study in hypogonadal men below provisos resembling real-life condition, Abstract Presented at the 22nd Annual European Association of Urology (EAU), 2007 8. A. Jardin, G. Wagner, S. Khory et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organisation (WHO), International Consultation on Urological Diseases (ICUD) and Societ� Internationale D'Urologie (SIU). p.713 9. R. C Rosen, W. A Fisher, I. Eardley, C. Neiderberger, A. Nada, M. Sand: The Multinational Men's Attitudes to Life Events and Sexuality (MALES) Study I, Prevalence of Erectile Dysfunction and Related Health Concerns in the General Population. Cur Med Res Op.
10. I. A Aytac, J. B McKinlay, R. J Krane: The expected world increase in erectile dysfunction between 1995 and 2065 and some in any way theory effect. BJU International 1999; 84:50-56 11. J. Southgate: New rival to Viagra extend the marketplace. Scrip World Pharmaceutical News, 2002 Bayer HealthCare Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's biggest, innovative concern in the healthcare and medical products industry and is underside in Leverkusen, Germany. The company combine the worldwide activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals division. The pharmaceuticals commercial operate under the pedal Bayer Schering Pharma AG. Bayer HealthCare's aim is to find and making products that will amend human and animal will worldwide.
Bayer Schering Pharma Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the subsequent to sphere of advice: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading station in specialized market worldwide. Using new planning, Bayer Schering Pharma aims to receive a chipping in to medical progress and strive to improve the quality of life.
Forward-looking ruling This synonym release contain forward-looking statements based on newsworthy assumption and forecasts made by Bayer Group government. Various specified and unknown risk, uncertainties and other factors could organize to things difference between the actual anticipated results, pecuniary situation, steps forward or performance of the company and the estimate given here. These factors include those clash in our population reports file with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company suppose no liability whatsoever to update these forward-looking statements or to conform them to future actions or development.
No comments:
Post a Comment